Literature DB >> 12810343

Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations.

Laura D Errante1, Ognen A C Petroff.   

Abstract

The effects of antiepileptic drugs, gabapentin, pregabalin and vigabatrin, on brain gamma-aminobutyric acid (GABA), glutamate and glutamine concentrations were studied in Long Evans rats using proton magnetic resonance spectroscopy (MRS) of perchloric acid extracts. Cellular glutamate concentrations significantly decreased by 7% (P<0.05) 2 hours after intraperitoneal injection of 100mg/kg gabapentin and 4% (P<0.05) with 1000 mg/kg. No differences were observed in cellular GABA and cellular glutamine concentrations in rats treated with gabapentin. Pregabalin, an analogue of gabapentin, significantly decreased cellular glutamate concentrations by 4% (P<0.05), while no effect was observed on cellular GABA or glutamine concentrations in the healthy rat forebrain. Vigabatrin, used as a positive control to increase GABA levels, produced a 50% increase in cellular GABA compared to saline treated rats (P<0.003). Although, gabapentin and pregabalin are anticonvulsants designed to mimic GABA, these drugs do not raise cellular GABA levels acutely but modestly decreased cellular glutamate levels in our healthy rat forebrain model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810343     DOI: 10.1016/s1059-1311(02)00295-9

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  26 in total

Review 1.  New drugs for the treatment of epilepsy: a practical approach.

Authors:  S Beyenburg; J Bauer; M Reuber
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

2.  Effect of Primidone on Dentate Nucleus γ-Aminobutyric Acid Concentration in Patients With Essential Tremor.

Authors:  Elan D Louis; Nora Hernandez; Jonathan P Dyke; Ruoyun Ma; Ulrike Dydak
Journal:  Clin Neuropharmacol       Date:  2016 Jan-Feb       Impact factor: 1.592

Review 3.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

4.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

5.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

6.  Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes.

Authors:  M Kammerer; M P Rassner; T M Freiman; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

7.  Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-11-19       Impact factor: 2.505

Review 8.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

9.  Skimmetin/osthole mitigates pain-depression dyad via inhibiting inflammatory and oxidative stress-mediated neurotransmitter dysregulation.

Authors:  Lovedeep Singh; Anudeep Kaur; Saweta Garg; Rajbir Bhatti
Journal:  Metab Brain Dis       Date:  2020-09-01       Impact factor: 3.584

10.  Pregabalin for the management of partial epilepsy.

Authors:  Philippe Ryvlin; Emilio Perucca; Sylvain Rheims
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.